Kenna R. Mills Shaw, PhD

Recommendations to address limitations in more widespread use of reflex testing in community oncology.

Expectations regarding the future utilization of comprehensive genomic profiling in clinical practice to assess patients with solid tumor cancers.

Variables that impact decisions to initiate therapy for solid tumor cancers versus wait for results of genomic profiling assays.

Oncologists explain scenarios for which they may retest patients previously assessed via genomic profiling.

Oncologists describe how they use molecular profiling in their practices to assess patients with solid tumor cancers.

Payer response to supporting decisions for coverage of comprehensive genomic profiling in oncology.

The rationale for migrating away from single, spot testing to comprehensive genomic profiling assays in oncology.

Oncologists who manage patients with solid tumors compare and contrast current comprehensive molecular assays being used in clinical practice and discuss reimbursement criteria with payer, Eugean Jiwanmall, MPH, MBA.

Information that can be extracted from results of comprehensive genomic profiling assays and used to guide treatment decisions in oncology.